With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

The company is submitting the Hunter syndrome treatment for U.S. approval on a ... The other treatment, RGX-111, treats ...

Regenxbio (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment ...

Plus: Rockville gene therapy company inks deal; Pioneering politician from Montgomery County celebrated with portrait ...

The company is submitting the Hunter syndrome treatment for U.S ... treats another type of mucopolysaccharidosis called Hurler syndrome. It’s earlier in clinical testing. Regenxbio will lead ...

The partnership between REGENXBIO and Nippon Shinyaku is more than just a standard collaboration—it’s a bold, forward-looking venture aimed at bringing revolutionary gene therapies to market for rare, ...

REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of ...

Shares of Regenxbio Inc . (NASDAQ: RGNX) surged 18.4% in pre-open trading Tuesday following the announcement of a strategic partnership with Nippon Shinyaku Co., Ltd. for the development and ...

REGENXBIO (NASDAQ:RGNX) and Nippon Shinyaku have entered into a partnership for the development and commercialization of REGENXBIO's gene therapies RGX-121 for the treatment of Hunter syndrome, or MPS ...

In a deal potentially worth $810 million for Regenxbio Inc., Nippon Shinyaku Co. Ltd. is partnering on the U.S. and Asian development and commercialization of iduronate-2-sulfatase enzyme RGX-121 for ...

today announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for ...

III study in treating thyroid eye disease. The privately held company posted top-line efficacy and safety results from a phase IIb/III study of its lead candidate, linsitinib, which hits its primary ...